The Non-Malignant Channel is supported with funding from Agios (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2024 | Preconditioning prior to non-myeloablative matched sibling donor HSCT in patients with SCD
Elisabeth Dovern, MD, Amsterdam UMC, Amsterdam, Netherlands, shares insights into azathioprine/hydroxyurea preconditioning prior to non-myeloablative matched sibling donor hematopoietic stem cell transplantation (HSCT) in adults with sickle cell disease (SCD). The addition of the preconditioning phase resulted in high overall survival (OS) and enabled all patients to discontinue immunosuppressive treatment after one year. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
